SAN DIEGO, March 20, 2018 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces the presentation of analytical and clinical data
for its Target Selector™ liquid biopsy assay platforms at the
GTCbio 11th Biomarker Summit being held March
27-28, 2018 in San Diego.
Tony J. Pircher, Ph.D., Biocept's
Director of Immunochemistry, will serve as moderator for the
Oncology Biomarker session. To begin the session, he will present
"Utilizing Circulating Tumor Cells to Identify Predictive and
Prognostic Biomarkers." Additionally, Biocept will present a poster
at the conference entitled "Microfluidic Assay Detects dMMR in
Circulating Tumor Cells (CTCs)."
"In these data sets, we demonstrate the ability of our
circulating tumor cell (CTC) and circulating tumor DNA (ctDNA)
platforms to detect predictive and prognostic biomarkers from a
simple blood sample, which can help physicians select personalized
treatment regimens for their patients with cancer," said Dr.
Pircher. "Our liquid biopsy assays can be particularly useful when
there is insufficient sample material to perform a tissue biopsy or
when a tissue biopsy has proven inadequate for identifying
actionable biomarkers required to support the use of targeted drug
therapy."
"We look forward to showcasing the capabilities of our liquid
biopsy technology at this year's Biomarker Summit," stated
Michael W. Nall, Biocept's President
and CEO. "Our aim is to help physicians identify clinically
actionable biomarkers as rapidly as possible with our Target
Selector CTC and ctDNA platforms in order to enable timely and
better informed treatment selection."
About Biomarker Summit 2018
Sponsored by GTCbio, Biomarker Summit 2018 is a meeting place
for scientists and researchers to discuss all aspects of the
biomarker and diagnostic development process from discovery to
translation to commercialization. A wide variety of important
topics will be covered including biomarker identification,
validation, and translation strategies, bioinformatics and systems
biology approaches to personalized medicine, big data analytics and
management, regulatory and reimbursement trends, companion
diagnostics development, and much more. Through scientific
presentations, case studies and panel discussions, these areas will
be addressed in an interactive environment with perspectives from
industry, academia and the public.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the
platform has demonstrated the ability to identify cancer mutations
and alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
diagnosis and treatment of cancer, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-recent-advances-in-biomarker-identification-from-liquid-biopsies-at-gtcbios-11th-biomarker-summit-300616160.html
SOURCE Biocept, Inc.